|
1.
|
海外欧文誌原著
|
Trastuzumab Deruxtecan for Human Epidermal Growth Factor Receptor 2-Expressing Advanced or Recurrent Uterine Carcinosarcoma (NCCH1615): The STATICE Trial. 2023/05
|
|
2.
|
海外欧文誌原著
|
Co-Clinical Study of [fam-] Trastuzumab Deruxtecan (DS8201a) in Patient-Derived Xenograft Models of Uterine Carcinosarcoma and Its Association with Clinical Efficacy. 2023/06
|
|
3.
|
海外欧文誌原著
|
Durvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase III DUO-E Trial. 2024/01
|
|
4.
|
海外欧文誌原著
|
Folate receptor alpha is widely expressed and a potential therapeutic target in uterine and ovarian carcinosarcoma. 2023/09
|
|
5.
|
海外欧文誌原著
|
Discordances in expression of human epidermal growth factor receptor 2 between primary and metastatic uterine carcinosarcoma: A proposal for HER2-targeted therapy specimen selection. 2023/08
|
|
6.
|
国内和文誌原著
|
【各科・各部門の救急診療】広島市民病院産婦人科の緊急手術の現状 2009/03
|
|
7.
|
国内和文誌原著
|
【良性腫瘍性疾患】CA125高値を伴い、卵巣癌との鑑別が困難であった巨大卵巣莢膜細胞腫によるMeigs症候群の1例 2010/03
|
|
8.
|
国内和文誌総説
|
不正性器出血を認める子宮体癌に対する子宮体部(内膜)細胞診の有用性と限界 2010/05
|
|
9.
|
海外欧文誌原著
|
Intravenous/intraperitoneal paclitaxel and intraperitoneal carboplatin in patients with epithelial ovarian, fallopian tube, or peritoneal carcinoma: a feasibility study. 2012/01
|
|
10.
|
国内和文誌総説
|
【卵巣がん治療の個別化を目指す新たな局面】進行卵巣癌に対するネオアジュバント化学療法をめぐる論点 2014/07
|
|
11.
|
国内和文誌原著
|
パクリタキセル・カルボプラチン併用療法が奏功した卵巣および卵管癌肉腫の5例 2014/09
|
|
12.
|
海外欧文誌原著
|
Feasibility study of combination chemotherapy with paclitaxel, doxorubicin and cisplatin without prophylactic granulocyte colony-stimulating factor injection for intermediate-to-high risk or recurrent endometrial cancer. 2014/11
|
|
13.
|
海外欧文誌原著
|
The Risk of Ovarian Malignancy Algorithm (ROMA) as a Predictive Marker of Peritoneal Dissemination in Epithelial Ovarian Cancer Patients. 2015
|
|
14.
|
海外欧文誌原著
|
Advanced Mucinous Adenocarcinoma Arising from a Mature Cystic Teratoma: A Case Report and Literature Review. 2016
|
|
15.
|
海外欧文誌原著
|
Prognostic factors in patients with uterine carcinosarcoma: a multi-institutional retrospective study from the Japanese Gynecologic Oncology Group. 2016/02
|
|
16.
|
海外欧文誌原著
|
The Efficacy of Low-Dose Paclitaxel Added to Combination Chemotherapy of Carboplatin and Gemcitabine or Pegylated Liposomal Doxorubicin. 2016/03
|
|
17.
|
国内和文誌原著
|
悪性転化を伴う卵巣成熟嚢胞性奇形腫の4例 2016/03
|
|
18.
|
海外欧文誌原著
|
Optimal cytoreductive surgery in patients with advanced uterine carcinosarcoma: A multi-institutional retrospective study from the Japanese gynecologic oncology group. 2016/06
|
|
19.
|
海外欧文誌原著
|
Drug induced interstitial lung disease in oncology phase I trials. 2016/12
|
|
20.
|
海外欧文誌原著
|
A single-arm study evaluating bevacizumab, cisplatin, and paclitaxel followed by single-agent bevacizumab in Japanese patients with advanced cervical cancer. 2017/01
|
|
21.
|
海外欧文誌原著
|
Pazopanib as a second line treatment for uterine and ovarian carcinosarcoma: a single institutional study. 2017/01
|
|
22.
|
国内和文誌原著
|
[Combination Therapy of Pregabalin with Tramadol for Treatment of Peripheral Neuropathy in Patients with Gynecological Cancer Receiving Taxane Containing Chemotherapy]. 2017/03
|
|
23.
|
国内和文誌原著
|
婦人科がん化学療法に伴う末梢神経障害に対するプレガバリンおよびトラマドール併用の有用性 2017/03
|
|
24.
|
国内和文誌総説
|
希少がん治療のエビデンス創出に向けての国立がん研究センターの取り組み 2017/04
|
|
25.
|
国内和文誌総説
|
【がん診療-内科医が知りたい30のエッセンス】内科医が知っておくべきがん診療の基本 がん診療に必要な基本知識 薬物療法にはどのような治療がありますか 2017/07
|
|
26.
|
海外欧文誌原著
|
Phase 1 dose-escalation study of single-agent veliparib in Japanese patients with advanced solid tumors. 2017/09
|
|
27.
|
海外欧文誌原著
|
Prolonged Hypocalcemia Following a Single Dose of Denosumab for Diffuse Bone Metastasis of Gastric Cancer after Total Gastrectomy. 2017/11
|
|
28.
|
国内和文誌総説
|
PARP阻害薬 2018/01
|
|
29.
|
国内和文誌総説
|
【泌尿生殖器がん、婦人科がん、成人骨軟部肉腫、原発不明がん】肉腫 肉腫に対するチェックポイント阻害薬の開発動向 2018/01
|
|
30.
|
国内和文誌原著
|
[I. Clinical Development and Prospect of Chemotherapy for Uterine Carcinosarcoma]. 2018/02
|
|
31.
|
国内和文誌総説
|
【Gynecologic Tumor 婦人科腫瘍 婦人科Rare Tumorに対する化学療法】子宮癌肉腫に対する薬物療法の現状と今後の展望 2018/02
|
|
32.
|
海外欧文誌原著
|
Utility of Bayesian Single-Arm Design in New Drug Application for Rare Cancers in Japan: A Case Study of Phase 2 Trial for Sarcoma. 2018/05
|
|
33.
|
国内和文誌総説
|
【がん免疫療法の新展開-「知らない」ではすまない今のトレンド】婦人科がんに対する免疫療法 卵巣がんに対する免疫療法の動向 2018/06
|
|
34.
|
海外欧文誌原著
|
PIK3CA mutation profiling in patients with breast cancer, using a highly sensitive detection system. 2018/08
|
|
35.
|
海外欧文誌原著
|
Immune checkpoint inhibitors of CTLA4 and PD-1 for malignant melanoma arising in ovarian cystic teratoma: A case report. 2018/10
|
|
36.
|
国内和文誌総説
|
がん治療開発におけるPDXの活用と展望 2019/02
|
|
37.
|
国内和文誌原著
|
[Ifosfamide and Paclitaxel for Recurrent or Metastatic Uterine Carcinosarcoma]. 2019/10
|
|
38.
|
海外欧文誌原著
|
A phase II randomized controlled study of pegylated liposomal doxorubicin and carboplatin vs. gemcitabine and carboplatin for platinum-sensitive recurrent ovarian cancer (GOTIC003/intergroup study). 2019/10
|
|
39.
|
海外欧文誌原著
|
Subclinical thiamine deficiency identified by preoperative evaluation in an ovarian cancer patient: Diagnosis and the need for preoperative thiamine measurement. 2019/10
|
|
40.
|
国内和文誌総説
|
【希少がん、遺伝性腫瘍】希少がん 軟部肉腫に対する免疫チェックポイント治療 2019/10
|
|
41.
|
国内和文誌原著
|
転移再発子宮癌肉腫に対するイホスファミド・パクリタキセル併用療法(IT療法)の有用性に関する後方視的検討 2019/10
|
|
42.
|
海外欧文誌原著
|
Treatment Outcome of Second-Line Chemotherapy for Gynecologic Carcinosarcoma. 2020
|
|
43.
|
海外欧文誌原著
|
Survival outcomes in patients with human epidermal growth factor receptor 2 positive metastatic breast cancer administered a therapy following trastuzumab emtansine treatment. 2020/09
|
|
44.
|
国内和文誌総説
|
【周産期と悪性腫瘍】産科 妊娠期の診断・治療 乳がん 2020/09
|
|
45.
|
海外欧文誌原著
|
HER3 protein expression as a risk factor for post-operative recurrence in patients with early-stage adenocarcinoma and adenosquamous carcinoma of the cervix. 2020/10
|
|
46.
|
国内和文誌総説
|
【肉腫-基礎・臨床の最新知見-】肉腫の部位別治療と成績 軟部肉腫 子宮肉腫の薬物療法と最新の開発動向 2020/10
|
|
47.
|
海外欧文誌原著
|
Neoadjuvant chemotherapy promotes the expression of HER3 in patients with ovarian cancer. 2020/12
|
|
48.
|
海外欧文誌原著
|
Impact of ALK Inhibitors in Patients With ALK-Rearranged Nonlung Solid Tumors. 2021
|
|
49.
|
国内和文誌原著
|
[Ⅲ. Current Status and Future Development of Anti-Cancer Drugs in Rare Gynecologic Cancers-The Rise of Anti-HER2 Therapy]. 2021/02
|
|
50.
|
国内和文誌総説
|
婦人科癌2021 婦人科希少がんにおける薬物療法の開発 抗HER2療法の夜明け 2021/02
|
|
51.
|
国内和文誌総説
|
【希少がん-がん診療の新たな課題-】希少がん疾患各論 婦人科の腫瘍 子宮がん肉腫 2021/03
|
|
52.
|
海外欧文誌原著
|
Histopathological features of HER2 overexpression in uterine carcinosarcoma: proposal for requirements in HER2 testing for targeted therapy. 2021/06
|
|
53.
|
海外欧文誌原著
|
Visualization of Intratumor Pharmacokinetics of [fam-] Trastuzumab Deruxtecan (DS-8201a) in HER2 Heterogeneous Model Using Phosphor-integrated Dots Imaging Analysis. 2021/07
|
|
54.
|
海外欧文誌総説
|
Human epidermal growth factor receptor 2 targeted therapy in endometrial cancer: Clinical and pathological perspectives. 2021/10
|
|
55.
|
国内和文誌総説
|
【泌尿器生殖がん、婦人科がん】婦人科がん 子宮がんにおける分子標的薬のエビデンス 2021/10
|
|
56.
|
海外欧文誌原著
|
Clinical management and outcomes associated with etoposide, doxorubicin, and cisplatin plus mitotane treatment in metastatic adrenocortical carcinoma: a single institute experience. 2021/12
|
|
57.
|
海外欧文誌原著
|
Poor Treatment Outcomes with Second-Line Chemotherapy in Advanced Synovial Sarcoma. 2022
|
|
58.
|
海外欧文誌原著
|
Neutrophil-to-lymphocyte ratio as a prognostic factor for patients with metastatic or recurrent breast cancer treated using capecitabine: a retrospective study. 2022/01
|
|
59.
|
海外欧文誌原著
|
Association between effector-type regulatory T cells and immune checkpoint expression on CD8+ T cells in malignant ascites from epithelial ovarian cancer. 2022/04
|
|
60.
|
海外欧文誌原著
|
Diagnostic value of tumor markers in identifying favorable or unfavorable subsets in patients with cancer of unknown primary: a retrospective study. 2022/04
|
|
61.
|
国内和文誌総説
|
【泌尿器がん・婦人科がん薬物療法2022 update】婦人科がん 卵巣がんの分子標的治療 best combination/sequence 2022/10
|
|
62.
|
海外欧文誌原著
|
High expression of folate receptor alpha is associated with poor prognosis in patients with cervical cancer. 2022/11
|
|
63.
|
海外欧文誌原著
|
High mesothelin expression is correlated with non-squamous cell histology and poor survival in cervical cancer: a retrospective study. 2022/11
|
|
64.
|
海外欧文誌原著
|
Low HER2 expression is a predictor of poor prognosis in stage I triple-negative breast cancer. 2023
|
|
65.
|
海外欧文誌原著
|
Integrative prognostic analysis of tumor-infiltrating lymphocytes, CD8, CD20, programmed cell death-ligand 1, and tertiary lymphoid structures in patients with early-stage triple-negative breast cancer who did not receive adjuvant chemotherapy. 2023/01
|
|
66.
|
海外欧文誌原著
|
Changes in HER3 expression profiles between primary and recurrent gynecological cancers. 2023/02
|
|
67.
|
海外欧文誌原著
|
Impact of adjuvant chemotherapy and radiotherapy on tumour-infiltrating lymphocytes and PD-L1 expression in metastatic breast cancer. 2023/02
|
|
68.
|
国内和文誌総説
|
子宮平滑筋肉腫治療の最前線 2023/03
|
|
69.
|
海外欧文誌原著
|
A case of vasculogenic mesenchymal tumor in the mediastinum: whole-exome sequencing reveals origin from pre-existing germ cell tumor. 2023/05
|
|
70.
|
海外欧文誌原著
|
Development of a Detection System for ESR1 Mutations in Circulating Tumour DNA Using PNA-LNA-Mediated PCR Clamping. 2023/06
|
|
71.
|
海外欧文誌原著
|
Lymphocyte-to-monocyte ratio as a prognostic and potential tumor microenvironment indicator in advanced soft tissue sarcoma treated with first-line doxorubicin therapy. 2023/07
|
|
72.
|
海外欧文誌原著
|
Mismatch Repair Protein Expression in Endometrial Cancer: Assessing Concordance and Unveiling Pitfalls in Two Different Immunohistochemistry Assays. 2023/08
|
|
73.
|
海外欧文誌原著
|
Uterine Leiomyosarcoma Masquerading as a Malignant Perivascular Epithelioid Cell Tumor: A Diagnostic Challenge. 2023/08
|
|
74.
|
国内和文誌総説
|
【専攻医必携! 免疫チェックポイント阻害薬が変える子宮がん診療】子宮体がん編 分子標的薬レンバチニブとペムブロリズマブの併用療法の有害事象対策 2023/09
|
|
75.
|
国内和文誌総説
|
【専攻医必携! 免疫チェックポイント阻害薬が変える子宮がん診療】総論 子宮悪性腫瘍に対する免疫チェックポイント阻害薬の適応の変遷 2023/09
|
|
76.
|
国内和文誌総説
|
【希少がんに対する薬物療法の進歩】子宮肉腫・がん肉腫の診断と治療方針 2023/11
|
|
77.
|
海外欧文誌原著
|
Discordance in PD-L1 expression using 22C3 and SP142 assays between primary and metastatic triple-negative breast cancer. 2023/12
|
|
78.
|
海外欧文誌原著
|
Therapeutic target biomarkers of patient-derived xenograft models of gastric-type cervical adenocarcinoma. 2023/12
|
|
79.
|
海外欧文誌原著
|
Mesothelin expression in gynecologic carcinosarcoma: clinicopathological significance and correlation with HER2 expression. 2024/03
|
|
80.
|
海外欧文誌原著
|
Predicting Trabectedin Efficacy in Soft Tissue Sarcoma: Inflammatory Biomarker Analysis. 2024/05
|
|
81.
|
海外欧文誌原著
|
Predicting Trabectedin Efficacy in Soft Tissue Sarcoma: Inflammatory Biomarker Analysis. 2024/05
|
|
82.
|
海外欧文誌原著
|
Trop-2 expression and the tumor immune microenvironment in cervical cancer. 2024/05
|
|
83.
|
海外欧文誌原著
|
Unveiling pembrolizumab effectiveness in diverse subtypes of MSI-high endometrial cancers. 2024/05/01
|
|
84.
|
海外欧文誌原著
|
Trop-2 expression and the tumor immune microenvironment in cervical cancer. 2024/05/08
|
|
85.
|
海外欧文誌原著
|
Folate Receptor Alpha Expression and the Tumor Immune Microenvironment in Patients with Cervical Cancer. 2024/06/12
|
|
86.
|
海外欧文誌原著
|
HER2-negative or low expression as an unfavorable prognostic factor in patients with stage I/II uterine carcinosarcoma. 2024/07/02
|
|
87.
|
海外欧文誌原著
|
Efficacy and safety of nivolumab monotherapy in patients with unresectable clear cell sarcoma and alveolar soft part sarcoma (OSCAR Trial/NCCH1510). 2024/07/30
|
|
88.
|
海外欧文誌原著
|
Clinicopathological and prognostic features of HER2-null and HER2-low advanced breast cancer treated with eribulin or capecitabine. 2024/08/14
|
|
89.
|
海外欧文誌原著
|
The efficacy and safety of lenvatinib plus pembrolizumab therapy in patients with uterine carcinosarcoma. 2024/10
|
|
90.
|
海外欧文誌原著
|
Development of Antibody–Drug Conjugates for Malignancies of the Uterine Corpus: A Review 2025/02
|
|
91.
|
海外欧文誌原著
|
Establishing a comprehensive panel of patient-derived xenograft models for high-grade endometrial carcinoma: molecular subtypes, genetic alterations, and therapeutic target profiling. 2025/04/07
|
|
5件表示
|
|
全件表示(91件)
|
